ELI LILLY AND COMPANY Commitments, Fair Value Disclosure
ELI LILLY AND COMPANY (LLY) had Commitments, Fair Value Disclosure of $163.50 million as of 2010-12-31, per its 10-K filed 2011-02-22.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Net Asset (Liability)
us-gaap:CommitmentsFairValueDisclosure · last filed 2011-02-22
- 2010-12-31: Commitments, Fair Value Disclosure $163.50M.
- 2010-09-30: Commitments, Fair Value Disclosure $103.30M.
| Period end | Commitments, Fair Value Disclosure |
|---|---|
| 2010-12-31 | $163.50M 10-K · filed 2011-02-22 |
| 2010-09-30 | $103.30M 10-Q · filed 2010-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |